These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22985602)

  • 1. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
    Fernández M; Barcia E; Fernández-Carballido A; Garcia L; Slowing K; Negro S
    Int J Pharm; 2012 Nov; 438(1-2):266-78. PubMed ID: 22985602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease.
    Kanwar N; Bhandari R; Kuhad A; Sinha VR
    Drug Deliv Transl Res; 2019 Oct; 9(5):891-905. PubMed ID: 30877626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective novel delivery strategy of rasagiline for Parkinson's disease.
    Fernández M; Negro S; Slowing K; Fernández-Carballido A; Barcia E
    Int J Pharm; 2011 Oct; 419(1-2):271-80. PubMed ID: 21807080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of clioquinol on human neuronal-like cells: a new formulation of clioquinol-loaded PLGA microspheres for Alzheimer's disease.
    Barcia E; Salama A; Fernández-Carballido A; Negro S
    J Drug Target; 2011 Sep; 19(8):637-46. PubMed ID: 20945972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.
    Jiang Y; Zhang X; Mu H; Hua H; Duan D; Yan X; Wang Y; Meng Q; Lu X; Wang A; Liu W; Li Y; Sun K
    Drug Deliv; 2018 Nov; 25(1):143-152. PubMed ID: 29275639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism.
    Negro S; Boeva L; Slowing K; Fernandez-Carballido A; Garcia-García L; Barcia E
    Curr Pharm Des; 2017; 23(23):3423-3431. PubMed ID: 27779080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
    Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
    J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PLGA hydrophilia on the drug release and the hypoglucemic activity of different insulin-loaded PLGA microspheres.
    Presmanes C; de Miguel L; Espada R; Alvarez C; Morales E; Torrado JJ
    J Microencapsul; 2011; 28(8):791-8. PubMed ID: 21967461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method.
    He J; Zhou Z; Fan Y; Zhou X; Du H
    J Microencapsul; 2011; 28(8):763-70. PubMed ID: 22034953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced targeting efficiency of PLGA microspheres loaded with Lornoxicam for intra-articular administration.
    Zhang Z; Bi X; Li H; Huang G
    Drug Deliv; 2011; 18(7):536-44. PubMed ID: 21812757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique.
    Paillard-Giteau A; Tran VT; Thomas O; Garric X; Coudane J; Marchal S; Chourpa I; Benoît JP; Montero-Menei CN; Venier-Julienne MC
    Eur J Pharm Biopharm; 2010 Jun; 75(2):128-36. PubMed ID: 20226857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure.
    Checa-Casalengua P; Jiang C; Bravo-Osuna I; Tucker BA; Molina-Martínez IT; Young MJ; Herrero-Vanrell R
    J Control Release; 2011 Nov; 156(1):92-100. PubMed ID: 21704662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline in Parkinson's disease.
    Youdim MB
    N Engl J Med; 2010 Feb; 362(7):657-8; author reply 658-9. PubMed ID: 20164492
    [No Abstract]   [Full Text] [Related]  

  • 19. Sustained delivery of endostatin improves the efficacy of therapy in Lewis lung cancer model.
    Wu J; Ding D; Ren G; Xu X; Yin X; Hu Y
    J Control Release; 2009 Mar; 134(2):91-7. PubMed ID: 19084038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline in Parkinson's disease.
    Schwarzschild MA
    N Engl J Med; 2010 Feb; 362(7):658; author reply 658-9. PubMed ID: 20187261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.